Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

2025-523815-12-00
Recruiting
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Phase 3 · Czechia, Germany, Spain, France, Greece, Italy, Poland · 59 sites
Registry update: 19 Oct 2026
NCT07649525
Recruiting
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Phase 3 · United Kingdom · 5 sites
Registry update: 15 Jul 2026
NCT07589634
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Phase 2 · Argentina, Australia, Spain, France, Greece, Hungary, Malaysia, Portugal, Sweden, United States · 60 sites
Registry update: 3 Nov 2026
NCT07764978
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Phase 3 · Australia, Brazil, Canada, Germany, Denmark, Spain, France, United Kingdom, Italy, Japan, South Korea, Poland, Sweden, Taiwan, United States · 110 sites
Registry update: 14 Aug 2026
NCT07660939
Recruiting
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
Phase 1 · China · 1 site
Registry update: 28 Sept 2026
NCT07555938
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Phase 3 · Australia, Brazil, Canada, China, Czechia, Germany, Denmark, Spain, France, United Kingdom, Greece, Israel, Italy, Japan, South Korea, Poland, Puerto Rico, United States · 113 sites
Registry update: 10 Nov 2026
NCT07558915
Recruiting
A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 · Australia, South Korea · 2 sites
Registry update: 9 Nov 2026
NCT06870760
Recruiting
Pre-malignant States to Hematologic Malignancies in Firefighters
Not applicable · United States · 1 site
Registry update: 13 Jul 2026
NCT06971848
Recruiting
Evaluation of Skin Tests in Biotherapy Allergies
Not applicable · France · 1 site
Registry update: 18 Jun 2026
NCT07742215
Recruiting
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Phase 3 · Belarus, Russia · 16 sites
Registry update: 3 Aug 2026
NCT07623798
Recruiting
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Phase 3 · China · 1 site
Registry update: 17 Sept 2026
2024-515900-38-00
Recruiting
LUMC-BOB1-B7-TCR.1 in relapsed and refractory B-cell malignancies
Phase 1/2 · Netherlands · 1 site
Registry update: 9 Feb 2026
NCT07200089
Recruiting
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Phase 1 · United States · 1 site
Registry update: 15 Oct 2026
NCT07674498
Recruiting
Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma
Not applicable · Belgium · 3 sites
Registry update: 29 Jun 2026
NCT07490613
Recruiting
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Phase 1 · China · 1 site
Registry update: 4 Jun 2026
NCT07581704
Recruiting
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
Phase 1 · United States · 1 site
Registry update: 4 Jun 2026
NCT07663253
Recruiting
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Not applicable · China · 13 sites
Registry update: 23 Jun 2026
NCT07689058
Recruiting
CAR-T in Relapsed/Refractory Multiple Myeloma
Phase 2 · Pakistan · 1 site
Registry update: 8 Jul 2026
NCT07559799
Recruiting
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
Not applicable · Germany · 1 site
Registry update: 26 Jun 2026
NCT07518186
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 · Australia, Brazil, Canada, China, Czechia, Germany, Spain, France, Greece, Israel, India, Italy, Japan, South Korea, Poland, Taiwan, United States · 173 sites
Registry update: 25 Sept 2026

Ordered by registry start date. Freshness and sponsorship never change the order.